Abstract

Gut microbiota modulation by a probiotic is a novel therapy for hypercholesterolemia mitigation. This study initially investigated the potential hypocholesterolemic effect of Bacillus sp. DU-106 in hypercholesterolemic rats and explored its potential relation with gut microbiota. Sprague–Dawley rats received a high-fat diet, or a high-fat diet supplemented with 7.5 × 10⁹ and 1.5 × 10¹⁰ CFU/kg bw/day Bacillus sp. DU-106 (low-dose and high-dose groups). At the end of 9 weeks, Bacillus sp. DU-106 treatment significantly decreased the body weight, liver index, and total cholesterol. 16S rRNA sequencing showed that Bacillus sp. DU-106 intervention significantly increased bacterial richness and particularly increased the genus abundance of Turicibacter, Acinetobacter, Brevundimonas, and Bacillus and significantly decreased the abundance of Ralstonia. Metabolomic data further indicated that the supplementation of Bacillus sp. DU-106 remarkably changed the gut metabolic profiles of hypercholesterolemic rats and, in particular, elevated the metabolites of indole-3-acetate, methylsuccinic acid, creatine, glutamic acid, threonine, lysine, ascorbic acid, and pyridoxamine. Spearman’s correlation analysis showed the close relation between the different genera and metabolites. In conclusion, Bacillus sp. DU-106 supplement ameliorated high-fat diet-induced hypercholesterolemia and showed potential probiotic benefits for the intestine.

Key points

• A novel potential probiotic Bacillus sp. DU-106 ameliorated hypercholesterolemia in rats.

• Bacillus sp. DU-106 supplement regulated gut microbiome structure and richness.

• Bacillus sp. DU-106 supplement changed metabolic profiles in high-fat diet rats.

• Significant correlations were observed between differential genera and metabolites.

中文翻译：

---

芽孢杆菌属的补充。DU-106减少高脂饮食大鼠的高胆固醇血症并改善肠道营养不良

摘要

益生菌对肠道菌群的调节是缓解高胆固醇血症的新疗法。这项研究最初调查了芽孢杆菌的潜在降胆固醇作用。DU-106在高胆固醇血症大鼠中的作用及其与肠道菌群的潜在关系。Sprague–Dawley大鼠接受高脂饮食，或高脂饮食补充7.5×10 ⁹和1.5×10 ¹⁰  CFU / kg bw /天芽孢杆菌属。DU-106（低剂量和高剂量组）。在9周结束时，芽孢杆菌属。DU-106治疗可显着降低体重，肝脏指数和总胆固醇。16S rRNA测序表明芽孢杆菌sp。DU-106干预显着增加了细菌的丰富度，特别是增加了Turicibacter，Acinetobacter，Brevundimonas和Bacillus的属丰度，并显着降低了Ralstonia的丰度。代谢组学数据进一步表明补充芽孢杆菌。DU-106显着改变了高胆固醇血症大鼠的肠道代谢谱，尤其是提高了吲哚-3-乙酸酯，甲基琥珀酸，肌酸，谷氨酸，苏氨酸，赖氨酸，抗坏血酸和吡ido胺的代谢产物。Spearman的相关分析显示了不同属与代谢产物之间的密切关系。结论，芽孢杆菌属。DU-106补充剂改善了高脂饮食诱导的高胆固醇血症，并显示出对肠道有益的益生菌益处。

关键点

•一种新型的潜在益生芽孢杆菌。DU-106改善了大鼠的高胆固醇血症。

•芽孢杆菌 DU-106补充剂可调节肠道微生物组的结构和丰富度。

•芽孢杆菌 DU-106补充剂改变了高脂饮食大鼠的代谢特征。

•观察到不同属和代谢物之间的显着相关性。